



## APAA: Asthma Pharmacogenetics across Ages

Guest Editors:

**Prof. Ann Chen Wu**

Center for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215-5301, USA

**Dr. Michael McGeachie**

Channing Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02215, USA

Deadline for manuscript submissions:

**closed (5 April 2022)**

### Message from the Guest Editors


Pharmacogenetics has had substantial impact in the treatment of some diseases, but despite much progress on the genetics of asthma, heterogeneity of asthma across the age spectrum has hindered translation.

This Special Issue will focus on age-dependent factors likely to yield important indicators of asthma drug response that are applicable to children and adults. A specific interest is genetic and genomic mechanisms regulating response to asthma treatments including inhaled steroids and beta2-agonists and the differences across the age spectrum.

Using age-dependent biomarkers to predict asthma drug response carries tremendous promise to improve asthma management by allowing clinicians to tailor asthma management to individual needs. Emerging results point to less asthma suffering and substantial cost-savings as the number of exacerbations from asthma will decrease.

This Special Issue of JPM: APAA will focus on all aspects of pharmacogenetics of asthma; the heterogeneity of asthma subtypes related to age; age-based genetic, metabolomic, transcriptomic, and other broad-based investigations of asthma pharmacology. We welcome all submissions related to these topics.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)